Who is the CEO of McKesson Canada?
The President of McKesson Canada is Dimitris Polygenis.
Key Details
- Role: President of McKesson Canada (the top executive position for the Canadian division).
- Appointment: Took office on October 1, 2025, succeeding Joan Eliasek.
- Background: Has over 20 years of experience with McKesson Canada, previously leading its Specialty Health, Retail, and Pharmaceutical business units.
- Parent Company CEO: Brian S. Tyler serves as the Chief Executive Officer of the parent organization, McKesson Corporation.
How much does the CEO of McKesson make a year?
The CEO of McKesson Corporation, Brian S. Tyler, received a total compensation of $24,213,044 for fiscal year 2026.
Like most top corporate executives, the vast majority of his pay is performance-based and tied to company stock rather than cash. His annual earnings break down as follows according to SEC proxy statements:
- Base Salary: $1,591,667
- Stock Awards: $17,201,202
- Bonus & Non-Equity Incentive Pay: $4,456,668
- Other Compensation: $963,507
This total is a 20.1% increase from his fiscal year 2025 total compensation, which was $20,161,714. Based on his total 2026 earnings, the CEO-to-median-employee pay ratio at McKesson stands at 357:1, where the median employee's annual compensation is $67,803.
Who owns McKesson Canada?
McKesson Canada is a wholly owned subsidiary of the American healthcare services company McKesson Corporation.
Ownership and Structure
- Parent Company: McKesson Corporation, which is headquartered in Irving, Texas.
- Core Business: It operates as Canada's largest pharmaceutical distributor, supplying hospitals, clinics, and pharmacies across the country.
- Pharmacy Banners: While it provides franchise and banner services to independent networks like I.D.A., Guardian, Remedy'sRx, and The Medicine Shoppe, it does not directly own these retail storefronts.
Recent Divestitures
- Rexall and Well.ca: McKesson Corporation previously owned the Rexall pharmacy chain and Well.ca, but sold both Canadian retail businesses to the Toronto-based private equity firm Birch Hill Equity Partners.
- Current Focus: The core distribution, pharmaceutical logistics, and specialty health operations in Canada remain under McKesson Corporation ownership.
Who is the current CEO of McKesson?
The current CEO of McKesson Corporation is Brian Tyler. He has served in this role since April 2019.
Who was the former CEO of McKesson?
The former long-time CEO of McKesson Corporation was John Hammergren, who served in the role from 1999 until his retirement on March 31, 2019. He was succeeded by the current CEO, Brian Tyler.
Key Details About John Hammergren
- Tenure: Led the company for nearly 20 years, making him one of the longest-serving chief executives in the healthcare sector.
- Growth: Oversaw massive financial growth, helping McKesson scale into a major Fortune 500 healthcare and pharmaceutical distribution giant.
- Transition: Formally stepped down on March 31, 2019, and passed leadership to then-President and COO Brian Tyler.
McKesson Explained: The $309 Billion Healthcare Giant Powering Pharmacies & Medical Supply Chains
Who is McKesson's largest customer?
McKesson's largest customer is CVS Health Corp., which accounts for approximately 24% of the company's total consolidated revenues.
Customer Concentration Details
- Revenue Share: Sales to CVS Health represent nearly a quarter of McKesson's overall annual revenue.
- Top Customers: The top 10 customers and group purchasing organizations (GPOs) combined account for a substantial majority of total revenue.
- Key Relationship: The long-term distribution agreement primarily supplies products to CVS retail, mail-order, and specialty pharmacies.
Is McKesson laying off?
Yes, McKesson is currently undergoing multiple rounds of layoffs and restructuring across several of its business segments and subsidiaries.
📊 Recent Layoff Activity
- Rx Savings Solutions: Cutting dozens of roles in Overland Park through January 2027.
- CoverMyMeds: Restructuring and eliminating positions in Columbus through early 2027.
- West Seneca, NY: Laid off 78 employees closing a fulfillment center in mid-2026.
- Facility Closures: Shuttered distribution centers in Rock Hill, SC and Rogers, MN previously.
💡 Why It Is Happening
- Cost Optimization: Part of a broader $200M–$250M restructuring plan.
- Operational Efficiency: Shifting focus from legacy services to modern tech solutions.
- Timeline: Restructuring efforts are expected to run through fiscal year 2029.
Why is McKesson falling?
McKesson (NYSE: MCK) recently faced short-term pullbacks due to a mix of broader market pressures, sector rotations, and company-specific headlines.
Key Pressures on the Stock
- Broader Market & Sector Weakness: Equities faced pressure from surging oil prices, escalating geopolitical conflicts, and hotter-than-expected inflation reports like the Producer Price Index (PPI).
- Cybersecurity Concerns: Investor hesitation grew following reports of a third-party cyber incident involving the exfiltration of data.
- Industry and Margin Headwinds: Trading has seen caution around drug pricing pressures, regulatory scrutiny, and slowing volume growth expectations for GLP-1 weight-loss drugs.
- Executive Stock Sales: Short-term sentiment dipped earlier when CEO Brian S. Tyler sold a portion of his shares under a pre-arranged trading plan.
Despite these near-term headwinds, McKesson Corporation Stock Quote has maintained strong long-term fundamentals, recently raising its full-year adjusted EPS guidance and pursuing growth in oncology and specialty care.
What is the McKesson controversy?
McKesson Corporation faced major controversy for failing to report suspicious, massive orders of prescription opioids to the Drug Enforcement Administration (DEA), which contributed heavily to the U.S. opioid epidemic.
Opioid Distribution and DEA Settlements
- 2008 Fine: McKesson paid a $13.25 million civil penalty for failing to report suspicious sales of hydrocodone to illegal internet pharmacies.
- 2017 Record Settlement: The company paid a record $150 million civil penalty to the U.S. government for continuing to miss or ignore suspicious orders of controlled substances after its prior agreement. The case involved delayed enforcement criticized by media investigations like 60 Minutes and The Washington Post.
- State Lawsuits: McKesson faced separate state-level legal actions, including a $37 million settlement with West Virginia regarding massive pill dumping in small communities.
Whistleblower Kickback Allegations
- Oncology Tools: A whistleblower lawsuit accused McKesson of providing free business-management and pricing tools (like Margin Analyzer) to oncologists as illegal kickbacks.
- Inducing Sales: The software allegedly induced doctors to purchase more expensive cancer drugs through McKesson as their primary wholesale supplier, defrauding Medicare and patients.
What is the biggest pharmaceutical company in Canada?
Bausch Health Companies is the largest pharmaceutical company headquartered in Canada by revenue and market capitalization, generating over $9 billion in annual revenue.
Major Canadian-Headquartered Companies
- Bausch Health Companies: Located in Laval, Quebec, it leads the country in overall revenue and market value.
- Apotex Inc.: Headquartered in Toronto, Ontario, it is the largest Canadian-owned and domestic generic pharmaceutical producer.
- Pharmascience: Based in Montreal, Quebec, it is another major Canadian-owned generic and specialty drug manufacturer.
Global Players with Large Canadian Operations
The broader pharmaceutical market in Canada is heavily populated by international giants:
- Johnson & Johnson: Holds one of the largest market shares for total prescription and consumer sales in Canada.
- Sanofi: Operates extensive biomanufacturing and research facilities, serving as a major biopharma manufacturer in the country.
- AstraZeneca: Maintains a massive research and development footprint across Canadian health sciences.